Ten­point re­veals pos­i­tive Phase 3 da­ta for vi­sion drug af­ter Vi­s­us merg­er

Ten­point Ther­a­peu­tics’ pres­by­opia drug showed “sig­nif­i­cant im­prove­ments” in near vi­sion and read­ing speed in a Phase 3 tri­al. The biotech said the re­sults keep it …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER